Recently, programmed cell death 1 (PD-1)/programmed death ligand-1 (PD-L1) blockade immunotherapy has emerged as a highly promising approach for the comprehensive treatment of NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.